PINK:CSLLY
CSL Ltd. Stock News
$94.01
-1.28 (-1.34%)
At Close: May 17, 2024
KING OF PRUSSIA, Pa., Aug. 9, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force
FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience
09:10am, Tuesday, 03'rd Aug 2021
KING OF PRUSSIA, Pa., Aug. 3, 2021 /PRNewswire/ -- CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug.
CSL Limited: Near-Term Outlook Mixed Despite New License Agreement
10:52am, Friday, 21'st May 2021
CSL Limited recently closed a license agreement for a haemophilia B gene therapy candidate which is positive, but there are still risks associated with competition and regulatory approvals. The compan
KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that in
Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation Challenge
07:30am, Friday, 14'th May 2021
NEW YORK, May 14, 2021 /PRNewswire/ -- Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a global b
CSL Limited (CSLLY) CEO Paul Perreault on Q2 2021 Results - Earnings Call Transcript
11:37pm, Wednesday, 17'th Feb 2021
CSL Limited (CSLLY) CEO Paul Perreault on Q2 2021 Results - Earnings Call Transcript
3 Coronavirus Stocks to Stay Miles Away From in 2021
07:05am, Tuesday, 12'th Jan 2021
Their coronavirus projects fell behind, faltered, or failed.
